Pitavastatin
Hmg Coa Reductase Inhibitors
- Drug class
- Hmg Coa Reductase Inhibitors
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 7
Overview
Pitavastatin is an active pharmaceutical ingredient in the Hmg Coa Reductase Inhibitors group (C10AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 6 | May 9, 2025 |
| US United States | FDA | 1 | January 16, 2026 |
GBUnited Kingdom· MHRA
6 products
Uses
Alipza is indicated for the reduction of elevated total cholesterol (TC) and LDL-C, in adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, and combined (mixed) dyslipidaemia, when response to diet and other non- pharmacological measures is inadequate.
How to take
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adult with primary hyperlipidemia. Adults with heterozygous familial hypercholesterolemia (HeFH).
Pediatric use information is approved for Kowa Co Ltd’s LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd’s marketing exclusivity rights, this drug product is not labeled with that information. Pitavastatin is a HMG-CoA reductase inhibitor (statin) indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: ( 1 ) Adult patients with primary hyperlipidemia.
Adults with heterozygous familial hypercholesterolemia (HeFH).
How to take
Drug interactions
Known interactions involving Pitavastatin. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL323630004 · revised May 9, 2025
- [2]FDA DailyMed · 0f11ee80-871e-4f… · revised January 16, 2026 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.